Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older
3 Articles
3 Articles
Moderna's new vaccine against respiratory syncytial virus (RSV), one of the leading causes of bronchiolitis, has shown strong protection against severe cases of infection among adults 50 years of age or older. The dose uses innovative messenger RNA (RNA) technology, adopted for the first time with the immunes against Covid-19. The vaccine, called mRESVIA, has already been approved by the United States Food and Drug Administration (FDA), a drug r…
Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older
A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) infections, 60.2% against RSV-associated emergency department or urgent care encounters and 81.8% against RSV-associated hospitalizations in a population of older U.S. veterans, according to a recent study in JAMA Network Open.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium







